



- 1 Figure S-1. Scattergram comparing delafloxacin MIC and 5- μ g disk zone diameters when testing 283 coagulase-negative staphylococci isolates
- 2 (includes 25 *S. haemolyticus*) from clinical trials, surveillance surveys, and pre-clinical development.




- 3
- 4 ^a Broken lines indicate selected breakpoint criteria approved by the U.S. FDA (1).

Figure S-2. Scattergram comparing delafloxacin MIC and 5-µg disk zone diameters when testing 104 *P. aeruginosa* isolates from clinical trials, surveillance surveys, and pre-clinical development.




^a Broken lines indicate selected breakpoint criteria approved by the U.S. FDA (1).

Figure S-3. Scattergram comparing delafloxacin MIC and 5-μg disk zone diameters when testing 82 *S. pyogenes* isolates from clinical trials, surveillance surveys, and pre-clinical development.




^a Broken lines indicate selected breakpoint criteria approved by the U.S. FDA (1).

Figure S-4. Scattergram comparing delafloxacin MIC and 5-μg disk zone diameters when testing 134 *S. anginosus* group isolates from clinical trials, surveillance surveys and pre-clinical development



^a Broken lines indicate selected breakpoint criteria approved by the U.S. FDA (1).

Figure S-5. Scattergrams comparing delafloxacin MIC and 5-µg disk zone diameters when testing 110 *E. faecalis* isolates from clinical trials, surveillance surveys, and pre-clinical development



^a Broken lines indicate selected breakpoint criteria approved by the U.S. FDA (1).

1. Baxdela. 2017. BAXDELA package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s0001bl.pdf. Accessed September 2017.